Why Achillion Pharmaceuticals Is Shooting 25% Higher Today
After the company updated investors on its second-quarter financials and the progress it's making in its clinical-stage drug pipeline, shares in Achillion Pharmaceuticals (NASDAQ: ACHN) are soaring 24% higher at 11:45 a.m. EDT today.
Since licensing its hepatitis C clinical-drug pipeline to Johnson & Johnson (NYSE: JNJ) in 2015, Achillion Pharmaceuticals has been knee-deep in developing new therapies for other indications. Yesterday afternoon, the company shared with investors its second-quarter performance and its clinical-stage pipeline progress.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Johnson & Johnson Aktie
149,42 €
0,36 %
Klare Kaufstimmung für Johnson & Johnson: Viel mehr Buy- als Sell-Einschätzungen.
Das Community-Kursziel von 194 € für Johnson & Johnson deutet auf eine deutliche Steigerung um mehr als 20% gegenüber dem aktuellen Kurs von 149.42 € hin.
